Sanofi购买Dren Bio 600M元抗体DR-0201 用于推进自发免疫疾病治疗。 Sanofi buys Dren Bio's $600M antibody DR-0201 to advance autoimmune disease treatments.

桑诺菲(Sanofi)是一家大型保健公司, 正在购买Dren Bio的DR-0201, 这是一种目标抗体, Sanofi, a major healthcare company, is acquiring Dren Bio's DR-0201, a targeted antibody for $600 million to enhance its immunology offerings. 针对肌肉细胞,DR-0201可消耗B细胞,从而可能重置免疫系统,并为自身免疫性疾病患者提供长期缓解. DR-0201 targets myeloid cells to deplete B-cells, potentially resetting the immune system and offering long-term relief to patients with autoimmune diseases. 这一收购旨在巩固Sanofi作为免疫学领导者的地位。 This acquisition aims to solidify Sanofi's position as a leader in immunology.